UK markets closed
NIKKEI 225
28,546.18-276.11(-0.96%)HANG SENG
29,391.26-767.75(-2.55%)CRUDE OIL
52.75-0.02(-0.04%)
Incyte Corporation (INCY)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
99.39-1.11 (-1.10%)
At close: 4:00PM EST
99.40 +0.01 (0.01%)
After hours: 4:45PM EST
| Previous close | 100.50 |
| Open | 100.21 |
| Bid | 96.82 x 900 |
| Ask | 102.46 x 1000 |
| Day's range | 98.28 - 101.22 |
| 52-week range | 62.48 - 110.37 |
| Volume | 874,632 |
| Avg. volume | 1,149,740 |
| Market cap | 21.766B |
| Beta (5Y monthly) | 0.96 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.55 |
| Earnings date | 09 Feb 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 105.69 |
- Zacks
Incyte's (INCY) BLA for Cancer Drug Accepted for Priority Review
Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.
- Business Wire
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Squamous Cell Carcinoma of the Anal Canal (SCAC)
- Business Wire
Incyte to Report Fourth Quarter and Year-End 2020 Financial Results
Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2020 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 9, 2021.
© 2021 Verizon Media. All rights reserved.
